Eli Lilly and Company
Profit after direct costs
Core business profitability
Bottom line profitability
Top line growth rate
Flow of revenue through cost categories to net income
| Item | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | YoY Change |
|---|---|---|---|---|---|---|---|
Total Revenue | 28.32B | 28.54B | 34.12B | 45.04B | 65.18B | 44.7% | |
| Cost of Revenue | (7.31B) | (6.63B) | (7.08B) | (8.42B) | (10.56B) | 25.5% | |
Gross Profit | 21.01B | 21.91B | 27.04B | 36.62B | 54.62B | 49.1% | |
| Operating Expenses | |||||||
| Research & Development | (6.93B) | (7.19B) | (9.31B) | (10.99B) | (13.34B) | 21.4% | |
| Selling, General & Administrative | (6.14B) | (6.07B) | (6.94B) | (8.13B) | (11.09B) | 36.4% | |
| General & Administrative | (6.14B) | (6.07B) | (6.94B) | (8.13B) | (11.09B) | 36.4% | |
| Depreciation & Amortization | (1.55B) | (1.52B) | (1.53B) | (1.77B) | (1.56B) | -11.5% | |
Operating Income (EBIT) | 7.93B | 8.65B | 10.79B | 17.50B | 29.70B | 69.7% | |
| Non-Operating Items | |||||||
| Interest Income | 25.40M | 62.80M | 173.60M | 175.20M | 153.30M | -12.5% | |
| Interest Expense | (339.80M) | (331.60M) | (485.90M) | (780.60M) | (795.30M) | 1.9% | |
| Other Income/Expenses (Net) | -1.78B | -1.85B | -4.23B | -4.82B | -3.96B | -17.8% | |
Income Before Tax | 6.16B | 6.81B | 6.55B | 12.68B | 25.73B | 102.9% | |
| Income Tax Expense | (573.80M) | (561.60M) | (1.31B) | (2.09B) | (5.09B) | 143.6% | |
Net Income | 5.58B | 6.24B | 5.24B | 10.59B | 20.64B | 94.9% | |
| Per Share Metrics | |||||||
| Earnings Per Share (Basic) | $6 | $7 | $6 | $12 | $23 | 95.6% | |
| Weighted Avg Shares Outstanding | 953.65M | 950.18M | 899.38M | 900.61M | 898.00M | -0.3% | |
| Weighted Avg Shares Outstanding (Diluted) | 953.65M | 950.18M | 903.28M | 904.06M | 898.00M | -0.7% | |
EBITDA | 8.04B | 8.66B | 8.57B | 15.23B | 27.94B | 83.5% |
Explore LLY
LLY in the Healthcare
Mega Cap